Q1 EPS Estimate for Halozyme Therapeutics Raised by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Research analysts at Zacks Research raised their Q1 2025 earnings per share estimates for Halozyme Therapeutics in a report released on Tuesday, December 10th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of $0.97 per share for the quarter, up from their prior forecast of $0.95. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2025 earnings at $1.30 EPS, Q1 2026 earnings at $1.40 EPS and Q2 2026 earnings at $1.41 EPS.

Other research analysts have also recently issued research reports about the stock. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research report on Monday, November 4th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. HC Wainwright reissued a “buy” rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, November 20th. Finally, JMP Securities upped their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $48.00 on Thursday. The stock has a fifty day simple moving average of $51.43 and a 200-day simple moving average of $53.92. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The stock has a market cap of $6.11 billion, a PE ratio of 15.89, a P/E/G ratio of 0.43 and a beta of 1.23. Halozyme Therapeutics has a twelve month low of $33.15 and a twelve month high of $65.53.

Insider Buying and Selling at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total transaction of $620,300.00. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,778,084.68. The trade was a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 40,000 shares of company stock valued at $2,242,100 in the last quarter. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors have recently bought and sold shares of the business. International Assets Investment Management LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $33,000. Skandinaviska Enskilda Banken AB publ purchased a new stake in Halozyme Therapeutics in the second quarter valued at $49,000. GAMMA Investing LLC boosted its stake in Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 350 shares in the last quarter. Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics during the third quarter worth about $57,000. Finally, FSC Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth about $65,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.